Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis. - Flanigan J; Kane S; Mirzayeh Fashami F; Zhou A; Almuallem L; Tindal M; Schauf M; Li E; Lyman GH (PharmacoEconomics - open, 2026)